RARE Overview
Upcoming Projects (RARE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RARE)
-
A look at the positive data from Mereo BioPharma's ongoing Phase 2/3 study of Setrusumab (UX143) in Osteogenesis Imperfecta
Tickers: MREO, RARE
Executed On: Jul 14, 2023 at 11:45 AM EDT -
A Second View: Discussing the recent Phase 2/3 data for Setrusumab currently in development to treat Osteogenesis Imperfecta in Pediatric and Young Adult patients
Tickers: MREO, RARE
Executed On: Nov 17, 2022 at 11:00 AM EST -
Discussing the recent Phase 2/3 data for Setrusumab currently in development to treat Osteogenesis Imperfecta in Pediatric and Young Adult patients
Tickers: MREO, RARE
Executed On: Oct 18, 2022 at 05:00 PM EDT -
A Second View: Examining the potential of Evkeeza (evinacumab) as a new treatment option for patients with Homozygous Familial Hypercholesterolemia (HoFH)
Tickers: REGN, RARE
Executed On: Mar 23, 2022 at 09:00 AM EDT -
Examining the potential of Evkeeza (evinacumab) as a new treatment option for patients with Homozygous Familial Hypercholesterolemia (HoFH)
Tickers: REGN, RARE
Executed On: Feb 24, 2022 at 11:00 AM EST
Upcoming & Overdue Catalysts (RARE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (RARE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
